About the Event
Mark Reisenauer, President, Astellas Pharma US
Astellas : Working to advance innovative science into proven value for patients
Successful biopharmaceutical innovation requires a collaborative scientific, financial and policy ecosystem that encourages high-risk investment in R&D and support for patient access to cutting-edge medicines. Mark Reisenauer, President, Astellas Pharma US, will discuss Astellas’ ongoing efforts to produce medical solutions that provide value to patients and the current landscape for life sciences innovation in the U.S.
Richard Katz, Publisher, Japan Economy Watch and Senior Fellow, Carnegie Council for Ethics in International Affairs
“Restoring Japan’s Leadership in Innovation”
Mr. Katz will discuss open innovation and how that applies to industries ranging from pharmaceuticals and electronics to more pedestrian things like household goods that a company by Johnson & Johnson would produce. He will also talk about how Japan compares in this area to the US and Europe, typically in the area of pharmaceuticals where Japan currently lags.
Secondly, Mr. Katz will talk about potentials for US-Japan cooperation in business and finance and University areas. One area is the area of open innovation and he will talk about activities already going on in Silicon Valley and elsewhere. A second is University cooperation in entrepreneurship education. A third is potential for US venture capital and private equity in Japan. And finally there is a potential for US direct investment particularly for profitable SMEs that face failure to do a lack of successors.
About the Speakers
Mark Reisenauer is President, Astellas Pharma US. In this role, he is responsible for the operations of Astellas Pharma across the U.S., a $4 billion affiliate of the Tokyo-based pharmaceutical company headquartered in Northbrook, Ill. with 1,200 employees. Astellas is a company dedicated to improving the health of people around the world through the provision of innovative pharmaceutical products.
Reisenauer was most recently Senior Vice President of Astellas’ Oncology business unit and joined Astellas in 2011 as Vice President of Oncology Sales and Marketing. During his tenure, Mark’s leadership has yielded the fastest-growing franchise in Astellas’ US portfolio, as Oncology franchise sales grew from less than 10 percent of sales to approximately 50 percent of US sales. He has been instrumental in bringing many new important oncology treatments to patients, including XTANDI® (enzalutamide), XOSPATA® (gilteritinib) and PADCEV™ (enfortumab vedotin-ejfv). All three products have become standards of care in their approved indications.
Prior to joining Astellas, Reisenauer served as Senior Vice President and Chief Commercial Officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning, and commercial launch planning. Previously, Reisenauer held various sales and marketing leadership roles at AstraZeneca, Bristol Myers Squibb, Pharmacia, and Abbott. Reisenauer earned a bachelor’s degree in political science from the University of Wisconsin.
Reisenauer serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization dedicated to advancing policies that ensure continued investment in biopharmaceutical innovation.
Richard Katz is Publisher, Japan Economy Watch, a free blog at https://richardkatz.substack.com/ and Senior Fellow, Carnegie Council for Ethics in International Affairs
He is also a special correspondent at Weekly Toyo Keizai, a leading Japanese business weekly. He authored two books on Japan. The first was Japan: The System That Soured—The Rise and Fall of the Japanese Economic Miracle (M.E. Sharpe, 1998), followed by Japanese Phoenix: The Long Road to Economic Revival (M.E. Sharpe, 2002). Toyo Keizai Shimposa published them in Japanese.
He has taught about Japan as an adjunct professor in economics at the State University of New York at Stony Brook and at the New York University Stern School of Business, and has testified several times before Congress. He regularly writes op-eds and essays for newspapers and magazines, including Voodoo Abenomics in the July-August 2014 issue of Foreign Affairs.
This event is part of the NAJAS/KKC Business Speaker Series sponsored by the National Association of Japan-America Societies and the Keizai Koho Center.